Search results | genmab

Reports

Partnering Agreements with Genmab

The Partnering Agreements with Genmab report provides an in-depth insight into the partnering interests and activities of one of the worlds leading biopharma companies.

Insights

Genmab: Partnering activity 2009-2014

Genmab, a top big biotech company, headquartered in Denmark is one of the leaders today in the human antibody therapeutics market for cancer treatment.

Genmab: Rapidly progressing in the field of antibodies

Genmab is an internationally recognised biotechnology company developing human antibody therapeutics primarily for cancer.

Genmab: Company profile

Summary

Dealmakers weekly review – July 17 2012 – Janssen, Evotec, Genmab, Luminex, Nektar

Dealmaking activity rebounds to a year’s high

Dealmakers weekly review – June 12 2012 – Merck & Co, Tesaro, Novartis, Genmab, Baxter, Chatham Therapeutics

Dealmaking very active at the start of June with seventy new partnering deals, twelve new M&A deals, and twenty-one financings

Seattle Genetics: Empowering monoclonal antibodies

Seattle Genetics is a biotech company developing and commercializing antibody-based therapeutics to improve the lives of people living with cancer.

Seattle Genetics : Biotech industry partnering activity 2009-2014

Seattle Genetics, a successful big biotech industry headquartered in Seattle, focuses its effort on advancing antibody drug conjugate technology targeted toward cancer treatment.

Top twenty partnering/licensing deals in 2012 had a combined value of over $20 billion

Analysis of data from the leading life science deals and alliances intelligence database Current Agreements and recently published Partnering Yearbook 2013 report series, shows that the top twenty partnering deals in the life sciences have a combined value of $20.6 billion

Current Agreements Deal Analysis Update: September 2012

This month we are providing you with an overview of deal analysis in the life sciences, covering partnering and M&A in August 2012

Current Agreements Deal Analysis Update: June 2012

This month we are providing you with an overview of deal analysis in the life sciences, covering partnering and M&A in May 2012

Events

Sorry, your search returned no results.


Deals

OMT joins in a pharma alliance with Genmab

Open Monoclonal Technology announced an pharma alliance with Genmab.

Genmab and Seattle Genetics become biotech partners for developing ADC

Seattle Genetics becomes a biotech partner of Genmab for developing antibody-drug conjugate (ADC).

Genmab has raised $183 million in private financing

Genmab has raised gross proceeds of DKK 998 million ($183 million) following pricing of its previously announced private placement financing.

Genmab receives $1 million milestone in biotech deals with Janssen

Genmab has reached another milestone in its DuoBody technology platform biotech deals with Janssen Biotech and its affiliates, triggering a $1 million payment.

Genmab big biotech deals with ADC Therapeutics for oncology drug development

Genmab, a big biotech company, and ADC Therapeutics have entered biotech deals for the co-development of a new antibody-drug conjugate product combining Genmab’s HuMax-TAC antibody and ADC Therapeutics’ PBD-based warhead and linker technology.

Genmab surges over Johnson & Johnson pharma partners pact

Johnson & Johnson, a big pharma company inked a pharma partners licensing pact with Genmab for its experimental treatment for multiple myeloma

Janssen inks biotech partnering with Genmab for antibody development

Genmab and Janssen Biotech, both big biotech companies has agreed to collaborate in biotech partnering agreement to create and develop antibodies using its DuoBody technology platform and will receive an upfront payment of $3.5 million.

A biopharma collaboration for big pharma Novartis and Genmab

Novartis, a big pharma company is paying Genmab $2 million up front as part of a biopharma collaboration to develop bispecific antibodies based on the latter’s DuoBody technology against two disease target combinations selected by Novartis

Genmab reaches second milestone in Lundbeck collaboration

Genmab announced it had reached the second pre-clinical milestone in the collaboration with H. Lundbeck, triggering a €1 million payment.

Genmab and Seattle Genetics expand antibody-drug conjugate (ADC)

Genmab and Seattle Genetics have announced they have entered into a second antibody-drug conjugate (ADC) research collaboration agreement.